BioRestorative Therapies (BRTX) Q4 2024 earnings summary

Executive summary

• Revenue increased 175% year-over-year to $401,000 for 2024, with significant operational and net loss improvements.

• Advanced clinical programs, including positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease and FDA Fast Track designation.

• Expanded regulatory clearances, including FDA IND for cervical discogenic pain and provisional NYSDOH license for allogeneic tissue processing.

• Continued advancement of ThermoStem preclinical program targeting obesity and metabolic disorders, with ongoing licensing discussions.

• Early commercial revenues from BioCosmeceuticals expected to become more consistent, with proprietary biologic serum launched and plans for broader product family.

Financial highlights

• Revenue for 2024 was $401,000, up from $146,000 in 2023, a 175% increase.

• Loss from operations improved 24% to $11.6 million from $15.2 million in 2023.

• Net loss was $9 million ($1.16 per share), a 14% improvement from $10.4 million ($2.47 per share) in 2023.

• Cash used in operating activities was $8.2 million; year-end cash, equivalents, and marketable securities totaled $10.7 million with no debt.

Outlook and guidance

• Management expects 2025 cash burn to be similar or slightly less than 2024, with further reductions anticipated in 2026 as enrollment winds down.

• Projected growth and improving financial performance may reduce dependence on capital markets.

• Plans to present more Phase 2 data, pursue accelerated regulatory pathways, and expand BioCosmeceutical product offerings.

• Ongoing discussions for potential licensing of ThermoStem metabolic IP and exploration of first-in-human clinical trial.